Compare · CRWD vs ORPH
CRWD vs ORPH
Side-by-side comparison of CrowdStrike Holdings Inc. (CRWD) and Orphazyme A/S (ORPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRWD and ORPH operate in Computer Software: Prepackaged Software (Technology), so they compete in similar markets.
- CRWD is the larger of the two at $190.29B, about 1086.7x ORPH ($175.1M).
- CRWD has hit the wire 44 times in the past 4 weeks while ORPH has been quiet.
- CRWD has more recent analyst coverage (25 ratings vs 0 for ORPH).
- Company
- CrowdStrike Holdings Inc.
- Orphazyme A/S
- Price
- -
- -
- Market cap
- $190.29B
- $175.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Computer Software: Prepackaged Software
- Computer Software: Prepackaged Software
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 44
- 0
- Recent ratings
- 25
- 0
CrowdStrike Holdings Inc.
CrowdStrike Holdings, Inc. provides cloud-delivered solutions for endpoint and cloud workload protection in the United States, Australia, Germany, India, Israel, Romania, and the United Kingdom. It offers 19 cloud modules on its Falcon platform through a software as a service subscription-based model that covers various security markets, such as corporate workload security, security and vulnerability management, managed security services, IT operations management, threat intelligence services, identity protection, and log management. The company primarily sells its platform and cloud modules through its direct sales team. CrowdStrike Holdings, Inc. was incorporated in 2011 and is headquartered in Sunnyvale, California.
Orphazyme A/S
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
Latest CRWD
- Director Gandhi Sameer K sold $1,404,909 worth of shares (1,809 units at $776.62) as part of a pre-agreed trading plan (SEC Form 4)
- PRESIDENT AND CEO Kurtz George sold $1,460,829 worth of shares (1,916 units at $762.44), decreasing direct ownership by 0.09% to 2,142,022 units (SEC Form 4)
- Director Gandhi Sameer K sold $2,419,423 worth of shares (3,191 units at $758.20) as part of a pre-agreed trading plan (SEC Form 4)
- PRESIDENT AND CEO Kurtz George sold $2,352,439 worth of shares (3,084 units at $762.79), decreasing direct ownership by 0.14% to 2,143,938 units (SEC Form 4)
- CrowdStrike Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits, Other Events
- CrowdStrike Reports First Quarter Fiscal Year 2027 Financial Results
- The Company Trying to Make Your AI Data Worthless to Hackers
- CrowdStrike Appoints Bartley Richardson as Chief AI and Autonomous Systems Officer
- PRESIDENT AND CEO Kurtz George sold $1,421,423 worth of shares (1,967 units at $722.63), decreasing direct ownership by 0.09% to 2,147,022 units (SEC Form 4)
- PRESIDENT AND CEO Kurtz George sold $1,486,491 worth of shares (2,193 units at $677.83), decreasing direct ownership by 0.10% to 2,148,989 units (SEC Form 4)
Latest ORPH
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 20-F filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form NT 20-F/A filed by Orphazyme A/S (Amendment)
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form NT 20-F filed by Orphazyme A/S